Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
Authors:
- Bérengère Dadone-MontaudiéBDBérengère Dadone-Montaudié
- Audrey Laroche-ClaryALAudrey Laroche-Clary
- Aline MongisAMAline Mongis
- Emmanuel ChamoreyECEmmanuel Chamorey
- Ilaria Di MauroIMIlaria Di Mauro
- Vanessa ChaireVCVanessa Chaire
- Pascal FinettiPFPascal Finetti
- Renaud SchiappaRSRenaud Schiappa
- François Le LoarerFLFrançois Le Loarer
- Isabelle Birtwisle-PeyrottesIBIsabelle Birtwisle-Peyrottes
- Jean-François MichielsJMJean-François Michiels
- François BertucciFBFrançois Bertucci
Open Access
Abstract
We aimed to evaluate the therapeutic potential of the pan-FGFR inhibitor erdafitinib to treat dedifferentiated liposarcoma (DDLPS). FGFR expression and their prognostic value were assessed in a series of 694 samples of well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). The effect of erdafitinib—alone or in combination with other antagonists—on tumorigenicity was evaluated in vitro and in vivo. We detected overexpression of FGFR1 and/or FGFR4 in a subset of WDLPS and DDLPS and demonstrated correlation of this expression with poor prognosis. Erdafitinib treatment reduced cell viability, inducing apoptosis and strong inhibition of the ERK1/2 pathway. Combining erdafitinib with the MDM2 antagonist RG7388 exerted a synergistic effect on viability, apoptosis, and clonogenicity in one WDLPS and two DDLPS cell lines. Efficacy of this combination was confirmed in vivo on a DDLPS xenograft. Importantly, we report the efficacy of erdafitinib in one patient with refractory DDLPS showing disease stabilization for 12 weeks. We provide evidence that the FGFR pathway has therapeutic potential for a subset of DDLPS and that an FGFR1/FGFR4 expression might constitute a powerful biomarker to select patients for FGFR inhibitor clinical trials. In addition, we show that combining erdafitinib with RG7388 is a promising strategy for patients with DDLPS that deserves further investigation in the clinical setting.Keywords
This publication has 49 references indexed in Scilit:
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasCell, 2017
- Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasOncotarget, 2017
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2016
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialJournal of Clinical Oncology, 2016
- Genomic landscape of liposarcomaOncotarget, 2015
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcomaCancer, 2008
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal of Cancer, 2005